Search Results

SVS Issues Commentary on CREST-2

On behalf of the Society for Vascular Surgery (SVS), Ali AbuRahma, MD, Past President of SVS; Marc Schermerhorn, MD, Past Chair, SVS Document Oversight Committee; and Keith Calligaro, MD, President, SVS and SVS Executive Board, provided the following commentary on the CREST-2 results to Endovascular Today: The purpose of this commentary is to critically examine the CREST-2 results, discuss their implications for clinical decision-making for asymptomatic carotid artery disease, and guide clinicians toward optimizing patient outcomes.

VIVA 2011: Short- and Mid-Term ENGAGE Study Results for AAA Stent Graft

October 19, 2011—At the VIVA 2011: Vascular Interventional Advances meeting in Las Vegas, Nevada, Marc Schermerhorn, MD, presented short- and mid-term results from the ENGAGE registry.

Five-Year Gender Subset Data Presented From Medtronic's ENGAGE Registry

September 13, 2017—Medtronic announced that 5-year ENGAGE global registry data for the company's Endurant II abdominal aortic aneurysm stent graft system were presented by Marc Schermerhorn, MD, in a late-breaking clinical trial at the VIVA 17, Vascular Interventional Advances, conference held September 11–14 in Las Vegas, Nevada.

Silk Road Medical Announces Presentation of TCAR Data

June 29, 2018—Silk Road Medical, Inc. announced the presentation of real-world data from the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project, an initiative of the Society for Vascular Surgery’s (SVS) Vascular Quality Initiative.

Study Evaluates Long-Term Survival Rates of Endologix's Nellix EVAS System Compared With EVAR

April 25, 2018—Endologix, Inc. announced the results of a retrospective, propensity-weighted study of long-term survival using the company's Nellix endovascular aneurysm sealing (EVAS) system compared with traditional endovascular aneurysm repair (EVAR) in the treatment of abdominal aortic aneurysms (AAAs).

Study Suggests That AAA Patients Should Be Considered for Statin Therapy

August 7, 2018—The Society for Vascular Surgery (SVS) announced that new evidence has been published suggesting that statin therapy is associated with a significant survival benefit in patients undergoing abdominal aortic aneurysm (AAA) repair.

Renin-Angiotensin System Inhibitors Studied for Patients With Chronic Limb-Threatening Ischemia

February 28, 2018—The Society for Vascular Surgery (SVS) announced the publication of findings from a study demonstrating that physicians should consider prescribing high-dose angiotensin inhibitors for patients with chronic limb-threatening ischemia (CLTI).

VQI Study Shows Similar Outcomes for TCAR Versus CEA, With Lower CNI and OR Time

November 20, 2018—Transcarotid artery revascularization (TCAR) showed similar rates of in-hospital stroke and death yet shorter operating room (OR) time and fewer cranial nerve injuries (CNIs) than carotid endarterectomy (CEA) in a study presented at the 2018 VEITHsymposium in New York, New York.

Medtronic Begins US Postapproval Study of Endurant AAA Stent Graft

August 31, 2011—Medtronic, Inc. (Minneapolis, MN) announced the start of ENGAGE PAS, its US postapproval study of the Endurant AAA stent graft system for the treatment of abdominal aortic aneurysms (AAA).

Study Compares National Trends in Treatments for Claudication and Limb-Threatening Ischemia

October 4, 2011—The Society for Vascular Surgery (SVS) announced the publication of a study comparing the benefit of angioplasty versus bypass grafting as treatments for claudication and limb-threatening ischemia.

Study Suggests Use of Aortic Size Index May Improve AAA Repair Outcomes in Women

March 28, 2017—The Society for Vascular Surgery (SVS) announced that in a study published by Sarah E. Deery, MD, et al in Journal of Vascular Surgery (JVS), women appear to have worse mortality and morbidity outcomes than men after abdominal aortic aneurysm (AAA) repair (2017;65:1006–1013).

Shape Memory Medical’s AAA-SHAPE Pivotal Trial Commences

June 3, 2024—Shape Memory Medical Inc. announced that the first patient was treated in the AAA-SHAPE pivotal trial.